In the Tg2576 AD mouse model, an eight-month course of intranasal administration of exenatide combined with insulin resulted in enhanced learning abilities and a reduction in cortical amyloid-beta levels, although the decrease in amyloid-beta was not statistically significant [94]. The gene discussed is INS; the disease is Alzheimer disease.